Access to all documents and request for further information are available to all users at no cost. In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information may be shared with the owners of that document or information.
Vetter Pharma International GmbH
Number of staff: Approximately 3,000
Key Personnel: Max Horn, managing director; Thomas Otto, managing director; Peter Soelkner, managing director
Who we are:
Vetter is a leading contract development and manufacturing organization (CDMO) that specializes in the aseptic filling of syringes, cartridges and vials. The company has extensive experience with biologics and other complex compounds, including monoclonal antibodies, peptides, interferons and vaccines. Collaborating with pharma/biotech clients worldwide, Vetter supports products from preclinical development through global market supply. Through its U.S. and European facilities, Vetter Development Service provides state-ofthe- art support for early-stage products, with seamless transfer at Phase III to Vetter Commercial Manufacturing for large-scale production. The company offers state-of-the-art technology and innovative processes to promote product quality and maximize API yield.
Major Markets: Europe & North America
Vetter Development Service includes:
–Clinical trial manufacturing
Vetter Commercial Manufacturing includes:
–Fill and finish
–Product life cycle management
Vetter Packaging Solutions include:
–Customized packaging development
–Proven platform technologies
Dosage forms: Syringes, cartridges and vials